- Home
- ZEPP vs MPLT Comparison
ZEPP vs MPLT Comparison
Compare ZEPP & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZEPP | MPLT |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 696.3M | 594.8M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | ZEPP | MPLT |
|---|---|---|
| Price | $30.07 | $20.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | 191.2K | ★ 260.1K |
| Earning Date | 11-04-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $233,274,000.00 | N/A |
| Revenue This Year | $887.39 | N/A |
| Revenue Next Year | $26.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.64 | N/A |
| 52 Week Low | $2.13 | $12.24 |
| 52 Week High | $61.85 | $21.00 |
Technical Indicators
Market Signals| Indicator | ZEPP | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | N/A |
| Support Level | $26.48 | N/A |
| Resistance Level | $29.79 | N/A |
| Average True Range (ATR) | 2.37 | 0.00 |
| MACD | 0.95 | 0.00 |
| Stochastic Oscillator | 95.29 | 0.00 |
Price Performance
Historical ComparisonAbout ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About MPLT MapLight Therapeutics Inc. Common Stock
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.